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Background: There is increasing interest in screening for and diagnosing pulmonary
hypertension earlier in the course of disease. However, there is limited data on
cardiopulmonary abnormalities in patients with pulmonary hypertension newly diagnosed
in World Health Organization Function Class (WHO FC) I.
Methods: Data were retrieved from the ASPIRE registry (Assessing the Spectrum of
Pulmonary hypertension Identified at a REferral center) for consecutive treatment naïve
patients diagnosed with pulmonary hypertension by cardiac catheterization between
2001 and 2010 who underwent incremental shuttle walk exercise testing.
Results: Eight hundred and ninety-five patients were diagnosed with Group 1-5
pulmonary hypertension. Despite the absence of symptoms, patients in WHO FC I (n= 9)
had a significant reduction in exercise capacity (Incremental shuttle walk distance percent
predicted (ISWD%pred) 65 ± 13%, Z score −1.77 ± 1.05), and modest pulmonary
hypertension with a median (interquartile range) pulmonary artery pressure 31(20) mmHg
and pulmonary vascular resistance 2.1(8.2) Wood Units, despite a normal diffusion of
carbon monoxide adjusted for age and sex (DLco)%pred 99 ± 40%. Compared to
patients in WHO FC I, patients in WHO FC II (n = 162) had a lower ISWD%pred 43
± 22 and lower DLco%pred 65 ± 21%.
Conclusion: Our results demonstrate that patients with newly diagnosed pulmonary
hypertension with no or minimal symptomatic limitation have a significant reduction of
exercise capacity.
Keywords: incremental shuttle walk test, pulmonary hypertension, WHO functional class, screening, early
diagnosis, hemodynamics, exercise testing
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INTRODUCTION
Despite advances in treatment, pulmonary hypertension (PH)
remains a progressive life-limiting disease (1). Studies have
suggested that earlier intervention results in better outcomes
(2, 3). However, patients are usually diagnosed when the disease
is advanced (4, 5) and consequently there is interest in developing
strategies to enable earlier diagnosis (6). To diagnose pulmonary
hypertension prior to the development of significant disease,
it is recommended that people at increased risk of developing
pulmonary hypertension such as patients with systemic sclerosis
should be screened (7). These international guidelines emphasize
the importance of echocardiography in the screening process.
In systemic sclerosis where the prevalence of pulmonary
arterial hypertension is particularly high, investigators have also
recommended the use of diffusion capacity of the lung for carbon
monoxide percent predicted (DLco%pred) which is frequently
reduced in patients with systemic sclerosis and pulmonary
arterial hypertension (8–10). More recently a cross-sectional,
international study looked at a large number of candidate
biomarkers in systemic sclerosis to construct a model to aid
decisions to proceed to cardiac catheterisation (the DETECT
study) (11).
At rest the pulmonary circulation has large microcirculatory
reserves. These are recruited during exercise, increasing the
capillary surface area available for gas exchange and maintaining
a low pulmonary artery pressure despite increased flow (12). Any
reduction in pulmonary vasculature reserves may therefore be
first detected during exercise. Although exercise testing using
the 6-min walk test was included as a candidate marker in the
DETECT study, and may have been expected to contribute to an
early diagnostic model, it had no utility in the model constructed
to diagnose pulmonary arterial hypertension. This may reflect
the inability of the 6-min walk test to identify the presence of
early pulmonary vascular disease given its ceiling effect where
in mild disease 6min walking test distance no longer reflects
maximal oxygen aerobic capacity (13–15) or disease severity (16)
or be due to an inability of patients with systemic sclerosis to
exercise as a consequence of musculoskeletal disease. In addition,
a systematic review of studies looking at the correlation of the
New York Heart Association (NYHA) Classification and the 6-
min walk distance (6MWD) in patients with heart failure without
musculoskeletal disease (17) also found no significant difference
between asymptomatic/mildly symptomatic patients (NYHA I
and II).
The incremental shuttle walking test (ISWT) has no ceiling
effect (18) and correlates better with peak exercise capacity
than the 6-min walking test (19). We have hypothesized that
the incremental shuttle walking test will be reduced in patients
with pulmonary hypertension in World Health Organization
functional class I (WHO FC I) when the patients have either no
or minor symptoms of breathlessness.
METHODS
Data were retrieved from the ASPIRE registry (Assessing the
Spectrum of Pulmonary hypertension Identified at a REferral
center) for consecutive, treatment naïve patients diagnosed
with pulmonary hypertension between 2001 and 2010 (4). The
systematic assessment of the patients has previously described
in detail (4). Patients included in this retrospective study were
diagnosed as Group 1–5 PH and were required to have mean
pulmonary artery pressure at right heart catheterisation of at least
25 mmHg and had a baseline ISWT within 3 months of cardiac
catheterization.
Incremental Shuttle Walk Test
The ISWT was performed according to the method of Singh et al.
(20). Patients were asked to walk as far as possible around the
10m course keeping in time to an audio signal until they were too
breathless or could no longer keep up with the speed. The initial
walking speed was 0.50 m/s and this increased incrementally
every minute to a maximum of 2.37 m/s. Breathlessness was
measured at rest and at the end of the test using the modified
Borg scale. Heart rate was measured throughout the test. ISWT
distance (ISWD) percent predicted (ISWD%pred) and z score
were calculated for each patient based on sex, age and BMI
using the equation derived by Probst et al. (21). No supplemental
oxygen was used during testing. If patients could not walk or
could not walk without oxygen the distance was recorded as 0m.
Lung Function Tests
Lung function tests were performed in accordance to the
European Respiratory Society guidelines (22–25). Predicted
DLco (DLco%pred) and z score were calculated for each patient
FIGURE 1 | Patient flow diagram.
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TABLE 1 | Patient characteristics and hemodynamic parameters.
WHO functional class
I II III IV
n 9 162 592 132
Sex male/female % 44/56 46/54 38/62 37/63
Age years 51 ± 13 56 ± 16 61 ± 16* 64 ± 16
BMI kg/m2 28.2 ± 4.7 28.0 ± 6.1 27.7 ± 6.2 27.1 ± 6.6
Smoking % Never/Ex/Current 43/57/0 48/44/8 38/51/12 36/57/7
Pack years 10 ± 16 12 ± 19 17 ± 20 25 ± 30†
Oxygen therapy % None/LTOT/Other 100/0/0 89/6/5 62/32/7 26/68/6
HEMODYNAMICS
mRAP mmHg 8(8) 8(7) 9(8) 12(8)†
mPAP mmHg 31(20) 37(16) 45(17) 47(12)
sPAP mmHg 51(38) 58(25) 74(29) 75(24)
Wedge mmHg 16 ± 9 13 ± 6 12 ± 6 11 ± 5
CI L/min/m2 3.4 ± 1.8 3.1 ± 0.8 2.7 ± 0.8* 2.1 ± 0.6†
PVR Wood Unit 2.1(8.2) 3.6(3.8) 7.0(6.9)* 11.5(6.8)†
SmvO2 % 67 ± 6 67 ± 7 63 ± 9* 58 ± 9†
ISWT
ISWD m 450(150) 280(258)N 120(140)* 10(58)†
ISWD%pred 65(20) 42(28)N 20(21)* 3(9) †
ISWD Z score −1.77 ± 1.05 −2.36 ± 1.36N −3.11 ± 1.14* −3.48 ± 1.10†
Starting SaO2 % 96.7 ± 2.1 93.8 ± 4.2N 91.0 ± 6.3* 85.0†
Lowest SaO2 % 84.2 ± 10.5 83.4 ± 11.0 82.6 ± 11.2 79.1 ± 11.6†
Starting HR bpm 85. ± 14 82 ± 17 83 ± 17 85 ± 18
Highest HR bpm 144 ± 37 125 ± 30 114 ± 23* 110 ± 23
Resting SBP mmHg 125 ± 25 131 ± 22 127 ± 20* 117 ± 19†
Highest SBP mmHg 159 ± 11 158 ± 25 145 ± 27* 128 ± 24†
Borg dyspnea score
Pre-test 0.6 ± 0.7 0.7 ± 1.0 1.1 ± 1.3* 1.8 ± 1.4†
Post-test 3.8 ± 1.6 4.2 ± 1.9 4.3 ± 1.9 4.7 ± 2.0†
LUNG FUNCTION
FEV1%pred 97 ± 14 75 ± 23N 74 ± 21 67 ± 23†
FVC%pred 103 ± 17 87 ± 23 87 ± 23 81 ± 27
DLco mmol/min/kPa 7.6 ± 3.2 5.6 ± 2.2N 4.3 ± 2.0* 2.9 ± 1.7†
DLco%pred 99 ± 40 72 ± 24N 59 ± 22* 41 ± 21†
DLco Z score −0.57 ± 3.43 −2.22 ± 1.96N −3.45 ± 2.37* −5.69 ± 3.10†
Presented as mean ± SD for parametric data and median(interquartile range) for nonparametric data. Categorical variables were presented as %. ISWT, incremental shuttle walk test;
WHO FC, World Health Organisation functional class; BMI, body mass index; mRAP, mean right atrial pressure; mPAP, mean pulmonary arterial pressure; sPAP, systolic pulmonary arterial
pressure; CI, cardiac index; PVR, pulmonary vascular resistance; SmvO2, mixed venous oxygen saturation; ISWD, incremental shuttle walk test distance; %pred: percent predicted;
SaO2, oxygen saturation; HR, heart rate; SBP, systolic blood pressure; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLco, diffusion factor across the lung
for carbon monoxide; z score, standardized score; Np < 0.05 WHO FC I vs. WHO FC II; *p < 0.05 WHO FC II vs. WHO FC III;
†
p < 0.05 WHO FC III vs. WHO FC IV.
using the Global Lung Function Initiative (GLI) reference
equations (26).
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics
v19 (SPSS, Chicago, IL, USA). Data is presented as mean ±
SD for parametric data and median (interquartile range) for
nonparametric data. Categorical variables were presented as
%. To evaluate our hypothesis that the incremental shuttle
walking test will be reduced in WHO FC I, the main outcome
variable was ISWD%pred. DLco%pred was a secondary outcome
to be used in comparison to the ISWD. Pearson’s correlation
test was used to assess correlations between these parameters
and WHO FC and hemodynamic parameters. The student t-
test and Mann Whitney U-test and Kruskal-Wallis test were
used to compare groups. Event (death or transplantation)
free survival from date of diagnosis was estimated using
the Kaplan–Meier method with comparison between groups
performed by the log-rank test. Cox proportional hazards
regression analysis was used to assess the effect of ISWD%pred,
age, sex, BMI, mPAP and DLco on survival time. As left
to right shunt is known to result in high DLco%pred (27),
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TABLE 2 | Correlation of ISWD%pred with WHO FC, hemodynamics, dyspnea
score and DLco%pred.
N r 95% CI p
WHO FC 895 −0.576 −0.598 −0.553 < 0.001
mRAP 778 −0.238 −0.301 −0.175 < 0.001
sPAP 762 −0.145 −0.214 −0.075 < 0.001
mPAP 777 −0.171 −0.239 −0.103 < 0.001
PVR 755 −0.263 −0.327 −0.195 < 0.001
CI 754 0.271 0.139 0.336 < 0.001
SmvO2 762 0.284 0.217 0.348 < 0.001
Wedge 724 0.014 −0.059 0.087 0.697
Borg Pre 631 −0.366 −0.432 −0.297 < 0.001
Borg Post 617 0.032 0.111 −0.047 0.433
DLco%pred 815 0.371 0.311 0.413 < 0.001
ISWD%pred, Incremental Shuttle Walk Test distance percent predicted; WHO FC, World
Health Organization functional class; mRAP, mean right atrial pressure; sPAP, systolic
pulmonary arterial pressure; mPAP, mean pulmonary arterial pressure; PVR, pulmonary
vascular resistance; CI, cardiac index; SmvO2, mixed venous oxygen saturation; ISWD,
Incremental Shuttle Walk Test distance; %pred, percent predicted; DLco%pred, diffusion
factor across the lung for carbon monoxide percent predicted.
separate analyses were also performed omitting patients with
congenital heart disease. Post-hoc analyses were also performed
on the group of patients in WHO FC I and II with
pulmonary hypertension related to systemic sclerosis who had
undergone screening for PH. A p-value of <0.05 was deemed
statistically significant. Ethical approval was granted by the
North Sheffield Research Ethics Committee (Reference No.
06/Q2308/8).
RESULTS
During the duration of the study 895 patients were diagnosed
with pulmonary hypertension and met the entry criteria
(Figure 1). At diagnosis 9 patients (1%) were inWHO functional
class 1, and 162 (18%), 592 (66%), and 132 (15%) in WHO
Functional Class II, III, and IV, respectively. Of those in WHO
FC I, 3 had systemic sclerosis (one of whom had a PAWP
> 15 mmHg), 3 had congenital heart disease with left to
right shunts, 1 left heart disease, 1 chronic thromboembolic
pulmonary hypertension and 1 hereditary pulmonary arterial
hypertension.
Demographics and Pulmonary
Hemodynamics
Patients’ characteristics are shown in Table 1. Patients in
WHO FC I were not significantly different to patients in
the other WHO FC’s with respect to age, sex distribution
or smoking history. No patients in WHO FC I were on
oxygen therapy compared with 6% in WHO FC II. Patients
in WHO FC I had modest pulmonary hypertension: mPAP
median(Interquartile range) 31(20) mmHg, preserved
cardiac index (CI): mean ± standard deviation 3.4 ±
1.8 l/min/m2 with no significant difference compared to
WHO FC II.
Incremental Shuttle Walking Test and Lung
Function Testing
Incremental shuttle walking distances (absolute, %pred and
standardized (z) score) were all significantly higher inWHO FC I
compared to WHO FC II. In addition, resting oxygen saturation
pre-test was significantly higher in WHO FC I compared to
WHO FC II. There was no significant difference in Borg dyspnea
score between these 2 groups either pre- or post-ISWT and no
significant difference in highest heart rate or highest systolic
blood pressure measured. ISWD%pred correlated significantly
(p all <0.05) with WHO FC, mRAP, mPAP, sPAP, CI, PVR, and
SmVO2 (Table 2).
There were also significant differences in lung function
between WHO FC I and II. DLco, DLco%pred, DLco z score
and FVC were all significantly higher in WHO FC I. DLco%pred
correlated with WHO FC, CI, PVR, and SmVO2 but not mRAP,
mPAP, or sPAP. There was a stronger correlation of WHO FC
with ISWD%pred compared with correlation to DLco%pred,
−0.576 and−0.382, respectively.
Although there were significant correlations between WHO
FC and ISWD%pred and DLco%pred, there was heterogeneity
in ISWD%pred and particularly DLco%pred within each WHO
FC (Figure 2). Figures 3A,B show the median and interquartile
range of results for ISWD%pred and DLco%pred, respectively,
for all patients byWHOFC. A large interquartile range was noted
for DLco%pred in WHO FC I. When patients with congenital
heart disease were omitted from analysis (Figures 3C,D) the
interquartile range of DLco%pred in WHO FC I was reduced.
However, although ISWD%pred still discriminated between
patients in WHO FC I and II (63 ± 15 vs. 45 ± 23 p = 0.02),
DLco%pred (74 ± 14 vs. 69 ± 17) and FVC%pred (96 ± 12
vs. 89 ± 23) were no longer significantly different (p > 0.05).
Similar patterns of heterogeneity was seen in the frequency of
standardized scores.
To assess the suitability of the ISWT as a screening tool, cut-
off points using %pred and z-score were investigated. Figure 4
shows the percentage of patients with an ISWD%pred of <80%.
A greater percentage of patients were identified using a cut-
off of <80 ISWD%pred than by using the DLco%pred <80
cut-off. Figure 2 shows that for any given %pred cut-off point,
ISWD%pred will positively identify more of the PH patients than
DLco%pred. Using z scores, ISWD is again a better discriminator
than DLco (Figure 5). In WHO FC 1 44% of patients had an
ISWD below the 5th percentile and 78% were below the 10th
percentile. Overall 73% of patients inWHO FC I and II are below
the 5th percentile for ISWD compared to only 58% below the 5th
percentile for DLco. Eighty four percent vs. 66% respectively were
below the 10th percentile.
Survival Analysis
Kaplan-Meier survival analysis demonstrated that WHO FC was
a significant predictor of outcome with decreasing survival with
increasing WHO FC (p < 0.0001) (Figure 6). Multivariate Cox
survival analysis including the parameters ISWD%pred, age, sex,
BMI, mPAP and DLco showed that ISWD%pred remained a
significant predictor (p < 0.001) (Table 3).
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FIGURE 2 | Histogram of Incremental shuttle walk distance percent predicted (ISWD%pred) and Diffusing capacity across the lung for carbon monoxide percent
predicted (DLco%pred) frequencies by World Health Organization functional class.
DISCUSSION
To our knowledge we have shown for the first time that patients
with pulmonary hypertension in WHO FC I have a significant
reduction in exercise capacity compared to predicted values. We
have also demonstrated that exercise capacity is more sensitive
than measurements of gas transfer made at rest in identifying
patients with pulmonary hypertension in WHO FC I and WHO
FC II. A single cut-off point is often suggested for screening as it
is easy to remember and apply. We evaluated the use of a cut-off
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FIGURE 3 | Median and interquartile ranges for Incremental shuttle walk distance percent predicted (ISWD%pred) and Diffusing capacity across the lung for carbon
monoxide percent predicted (DLco%pred) by World Health Organization Functional Class (WHO FC) in (A,B) all patients and (C,D) with congenital heart disease
patients excluded. p < 0.05; *p < 0.005; ns, not significant.
point of 80%pred looking for early changes and found that 89%
of patients in WHO FCI were below this cut-off point. Whilst
traditionally the normal range for a lung function parameters
was considered as being between 80 and 120%pred it is known
now that this could lead to misdiagnosis (28). We therefore also
examined percentile scores as cut-off points and again found that
the ISWT was a sensitive test with 73% of patients in WHO FC I
and II below the 5th percentile for ISWD.
In addition to confirming the findings of previous studies
(4, 29, 30) that WHO FC has a significant impact on survival,
we have also demonstrated that in the absence of symptoms of
breathlessness or in the presence of mild symptoms (i.e. patients
in WHO FC 1/II) patients have a modest elevation of pulmonary
artery pressure at initial diagnosis. In contrast patients with
more severe symptoms of breathlessness (WHO FC III and
IV) had significantly higher mean pulmonary artery pressure
elevation. Therefore strategies to diagnose patients earlier when
they have less symptomatic limitation is likely to identify patient
with less severe pulmonary haemodynamic disease. Patients in
WHO FC I included 3 patients with systemic sclerosis who had
been identified from screening regimens and these patients had
only mild elevation of mean pulmonary artery pressure, median
27mmHg. Patients not undergoing regular screening, may also
have been referred on the basis of echocardiograms performed
for the assessment of incidental murmurs or on the basis of
morphological changes consistent with pulmonary hypertension
seen on cross sectional imaging.
It could be possible that there is some misclassification of
the patients as classification into WHO FC is limited by patient
and physician subjectivity and agreement between observers is
often poor (31). There are however significant differences in
ISWD%pred and DLco%predicted between FC I and II and
there is a trend for increased survival. Breathlessness post ISWT
is no greater in WHO FC I suggesting that the increased
distance walked is not due to increased effort. This study,
therefore, does emphasize that if we are to rely on self-reported
symptoms of breathlessness to diagnose pulmonary hypertension
then patients will have established hemodynamic changes of
pulmonary hypertension at the time of diagnosis.
Current ESC/ERS guidelines recommend the use of Doppler
echocardiography for screening for pulmonary hypertension in
at risk patients. Like all screening tools echocardiography has
limitations. In 10–20% of patients it is not possible to obtain
interpretable results and the precision of echocardiography
estimation of systolic pulmonary artery pressure can be poor (32).
To overcome these difficulties other data, using lung function
tests and utilizing gas transfer (which is reduced as a consequence
of vascular involvement), have been used inscreening algorithms.
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FIGURE 4 | Percentage of patients with Incremental shuttle walk distance
percent predicted (ISWD%pred) and Diffusing capacity across the lung for
carbon monoxide percent predicted (DLco%pred) less than 80%
predicted in (A) All patients (B) Patients with congenital heart disease
excluded by World Health Organization Functional Class (WHO FC).
Most work has been done in systemic sclerosis using DLco%pred.
Hanchulla et al. (9) in a Frenchmulti-center trial found that a low
DLco of<60% predicted was associated with a higher probability
of PAH with only 30% of the newly diagnosed patients having
a DLco > 60%pred. A UK study among 243 systemic sclerosis-
associated PH patients found that <10% had a DLco >60%pred
(10). Guidelines now suggest using a cut-off of DLco%pred
<60% as part of the screening algorithm indicative of possible
pulmonary hypertension in systemic sclerosis (33). This strategy
has been shown to successfully enrich this population of
patients undergoing right heart catheter to investigate possible
pulmonary hypertension (11). However, whilst this algorithm
has been used with some success in systemic sclerosis it is not
applicable in patients with pulmonary hypertension associated
with other aetiologies (34). Our study highlights the large range
of DLco%pred found inWHO FC I, even when omitting patients
with congenital heart disease. In contrast ISWD%pred correlated
well with WHO FC with <10% of patients in WHO FC I and II
having an ISWD >80%pred.
A number of studies have looked at the use of exercise testing
including cardiopulmonary exercise testing, exercise Doppler
FIGURE 5 | Percentage of all patients with Incremental shuttle walk distance
percent predicted (ISWD%pred) and Diffusing capacity across the lung for
carbon monoxide percent predicted (DLco%pred) less than (A) the 5th
percentile and (B) the 10th percentile World Health Organization Functional
Class (WHO FC).
echocardiography or diffusion capacity during exercise (35–39)
to try to detect loss of compliance in the cardiopulmonary
circulation earlier than parameters measured at rest but the tests
used are complex. The advantage of the ISWT for screening
is that it is a very simple test to perform and has been
shown to reflect disease severity without a ceiling effect (8).
Data from this study suggest it might be suited to detecting
early disease. Pulmonary arterial hypertension and chronic
thromboembolic pulmonary hypertension, for which specific
therapies exist, are rare and therefore early identification relies
on having a high degree of awareness in patients at risk and
deploying appropriate disease specific strategies. Reducing the
time to diagnosis and institution of treatment for patients with
pulmonary hypertension requires a number of complimentary
approaches and screening for pulmonary hypertension in at
risk groups is only one approach. In addition to considering
pulmonary hypertension in high risk groups (e.g., systemic
sclerosis, portal hypertension, HIV, family history of PAH), there
needs to be an increased awareness amongst patients to seek
advice when they have exercise limitation and for physicians
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FIGURE 6 | Kaplan Meier survival analysis by World Health Organisation
functional class.
TABLE 3 | Multivariate Cox survival analysis.
HR 95% CI p
ISWD%pred 0.983 0.975 – 0.990 <0.0001
Age 1.017 1.007 – 1.026 <0.0001
BMI 0.980 0.961 – 0.999 0.044
mPAP 1.022 1.011 – 1.032 <0.0001
DLco%pred 0.974 0.967 – 0.980 <0.0001
ISWD%pred, Incremental shuttle walk test percent predicted; BMI, body mass index;
mPAP, mean pulmonary arterial pressure; DLco%pred, diffusion factor across the lung
for carbon monoxide percent predicted; HR, hazard ratio; CI, confidence interval.
to more systematically assess the breathless patient. Our results
suggest that exercise limitation (identified using a maximal
exercise test) is an almost universal finding in patients with
pulmonary hypertension even in patients who are asymptomatic.
Further study is required to assess whether the incremental
shuttle walking test could be used as a first line investigation or
as part of a battery of tests to screen at risk patients, proceeding
to more complex testing if abnormal.
LIMITATIONS
This was a retrospective, single center study. Within the studied
population only 1% of patients were diagnosed in WHO FC
I and 18% in WHO FC II. These percentages are small (but
are very similar to those found in the Geissen Pulmonary
Hypertension Registry, which has 1.0% patients in WHO FC
I, and confirm the findings in other registries (4, 26) that the
majority of patients are diagnosed with PH inWHO FC III when
symptomatic and haemodynamic severity are advanced. Given
the small number of patients in WHO FC I, interpretation of
negative results must be viewed with caution Classification of
WHO FC may be limited by patient and physician subjectivity
and agreement between observers is often poor (31). However
in this study there appears to be a trend to increased survival
in WHO FC 1 patients and ISWD is significantly higher in
patients in WHO FC I. Although patient motivation could affect
distance walked, the ISWT is externally paced which limits
the effect of motivation and patients in WHO FC I did not
report a higher dyspnoea score post-test suggesting that the
difference in distance walked was not due to greater patient
effort.
CONCLUSION
Our results demonstrate that patients with newly diagnosed
pulmonary hypertension with no or minimal symptomatic
limitation have a significant reduction of exercise capacity.
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